Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Raimondi

Showing results (321-330 of 399) with videos related to

Pageof 40
Sort By:
Pediatric Blood & Cancer|June 18, 2011
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121)Prasad Mathew, Robert Gerbing, Todd A Alonzo, et al.
Leukemia|September 10, 2004
Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapseN Hijiya, A Gajjar, Z Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemiaC H Pui, J E Rubnitz, M L Hancock, et al.
Human Genetics|April 1, 2003
Polymorphisms in the MLL breakpoint cluster region (BCR)Deborah R Echlin-Bell, Lydia L Smith, Loretta Li, et al.
Journal of Hematology & Oncology|October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Leukemia|March 14, 2009
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1S Jeha, D Pei, S C Raimondi, et al.
Haematologica|September 9, 2017
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531Andrew P Voigt, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Cancer|July 19, 2011
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology GroupTodd M Cooper, Janet Franklin, Robert B Gerbing, et al.
Leukemia|February 16, 2000
Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignanciesM H Woo, J J Shuster, C Chen, et al.
Journal of Hematology & Oncology|December 2, 2016
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Pageof 40

Showing results (321-330 of 399) with videos related to

Sort By:
Pageof 40
Pediatric Blood & Cancer|June 18, 2011
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121)Prasad Mathew, Robert Gerbing, Todd A Alonzo, et al.
Leukemia|September 10, 2004
Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapseN Hijiya, A Gajjar, Z Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemiaC H Pui, J E Rubnitz, M L Hancock, et al.
Human Genetics|April 1, 2003
Polymorphisms in the MLL breakpoint cluster region (BCR)Deborah R Echlin-Bell, Lydia L Smith, Loretta Li, et al.
Journal of Hematology & Oncology|October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Leukemia|March 14, 2009
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1S Jeha, D Pei, S C Raimondi, et al.
Haematologica|September 9, 2017
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531Andrew P Voigt, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Cancer|July 19, 2011
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology GroupTodd M Cooper, Janet Franklin, Robert B Gerbing, et al.
Leukemia|February 16, 2000
Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignanciesM H Woo, J J Shuster, C Chen, et al.
Journal of Hematology & Oncology|December 2, 2016
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Pageof 40